FDA Grants RMAT Designation for VY-AADC for Parkinson’s Disease

(June 22, 2018) – Voyager Therapeutics announced that the US Food and Drug Administration granted regenerative medicine advanced therapy (RMAT) designation for VY-AADC gene therapy for treatment of Parkinson’s disease in patients with motor fluctuations refractory to medical management. Read more…